Liquidia (NASDAQ:LQDA) Stock: Insider Sarah Krepp Sells 5,245 Shares

Posted by Brian Himes on Oct 15th, 2026

Liquidia Corporation (NASDAQ:LQDA – Get Free Report) insider Sarah Krepp sold 5,245 shares of the firm’s stock in a transaction on Monday, October 12th. The stock was sold at an average price of $28.48, for a total value of $149,377.60. Following the completion of the sale, the insider directly owned 115,241 shares of the company’s stock, valued at $3,282,063.68. The trade was a 4.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 26.6%

Shares of Liquidia stock opened at $33.94 on Thursday. The company has a current ratio of 2.31, a quick ratio of 2.12 and a debt-to-equity ratio of 0.63. The company’s fifty day simple moving average is $62.30 and its two-hundred day simple moving average is $61.74. The company has a market cap of $3.04 billion, a P/E ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a 12-month low of $21.94 and a 12-month high of $93.61.

Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter last year, the company posted ($0.49) earnings per share. The firm’s revenue for the quarter was up 1842.1% compared to the same quarter last year. Research analysts anticipate that Liquidia Corporation will post 2.05 EPS for the current year.

Institutional Trading of Liquidia

A number of hedge funds have recently modified their holdings of LQDA. Globeflex Capital L P purchased a new stake in shares of Liquidia in the 2nd quarter worth about $175,000. Nykredit A S purchased a new position in Liquidia during the 2nd quarter valued at about $177,000. Hurley Capital LLC lifted its position in Liquidia by 140.7% during the 4th quarter. Hurley Capital LLC now owns 5,200 shares of the company’s stock valued at $179,000 after acquiring an additional 3,040 shares during the period. Apollon Wealth Management LLC bought a new stake in Liquidia during the first quarter worth about $247,000. Finally, Archer Investment Corp bought a new stake in Liquidia during the first quarter worth about $259,000. Institutional investors own 64.54% of the company’s stock.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

Positive Sentiment: The settlement allows Liquidia to continue commercializing YUTREPIA for pulmonary arterial hypertension (PAH) without interruption, removing a major source of legal and commercial uncertainty. Liquidia settlement announcement
Positive Sentiment: Preliminary third-quarter YUTREPIA sales reached $222.7 million, contributing to $396.1 million in cash and equivalents. Management said it expects ongoing sales and existing cash to fund settlement obligations and clinical programs without additional financing. RTTNews settlement report
Positive Sentiment: Analyst sentiment improved following the agreement. BTIG upgraded LQDA from “neutral” to “buy” with a $70 price target, while Lifesci Capital raised its rating to “outperform” and set a $59 target. Needham maintained “buy” but lowered its target to $58.
Positive Sentiment: Trading activity reflected strong investor interest, with call-option volume more than doubling its average level.
Neutral Sentiment: Liquidia agreed to pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to the antitrust litigation. The payments resolve the disputes but will significantly draw down cash.
Negative Sentiment: The company will not appeal the patent ruling and is removing the PH-ILD indication from YUTREPIA’s label. It also ended promotion of Treprostinil Injection, narrowing potential revenue opportunities. Zacks settlement analysis
Negative Sentiment: Multiple executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. Because the sales were planned and left executives with substantial holdings, they are a limited standalone signal, but broader insider activity remains heavily weighted toward selling.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on LQDA. Stephens set a $130.00 price target on shares of Liquidia in a research note on Friday, July 24th. BTIG Research raised Liquidia from a “neutral” rating to a “buy” rating and set a $70.00 price objective on the stock in a research report on Wednesday. Wedbush set a $58.00 target price on Liquidia in a report on Friday, October 2nd. Wells Fargo & Company upped their target price on Liquidia from $30.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, Lifesci Capital raised Liquidia from a “market perform” rating to an “outperform” rating and set a $59.00 target price for the company in a research report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $77.31.

Read Our Latest Stock Analysis on LQDA

About Liquidia

(Get Free Report)

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).